Industry Standard Research (ISR) announced the launch of a new and complimentary research report titled 2009 Biotechnology Industry Pulse. This report documents 112 biotech industry executives’ perspectives on the health and future of the biotechnology industry.
“Everyone has heard that access to capital has been severely restricted in the last year. We were determined to uncover how, if at all, this scarcity of capital has impacted biotechnology companies’ clinical development activities and how long any disruptions might be expected to last”, explained Kevin Olson, President, Industry Standard Research. Olson went on to state, “The results of the study show that while development has slowed for many companies, those with solid compounds continue to receive high valuations and have, in many cases, even accelerated their development timelines.”
Also detailed in the report are executives’ assessments of, and predictions for, volatility and consolidation across the industry; confidence in the small, VC-funded biotech model; and their preferences for various types of development models for their products.
Kevin Olson, President ISR, further explains: “We were struck by just how varied executives are in their views on the industry and their preferences for development models are far from uniform. I believe there’s a tendency in the CRO community to view this as a homogeneous customer segment but the data clearly indicate otherwise.”
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.